• 1
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER 1975-2001. Surveillance Research Program, Cancer Statistics Branch, National Cancer Institute, DCCPS, Bethesda, MD, 2004.
  • 2
    Thorn M, Bergstrom R, Johansson AM, Ramstrom L, Persson I, Malmstrom PU. Trends in urinary bladder cancer incidence in Sweden 1960-93 with special reference to histopathology, time period, birth cohort, and smoking. Cancer Causes Control 1997; 8: 5607.
  • 3
    Hayne D, Arya M, Quinn MJ, Babb PJ, Beacock CJM, Patel HRH. Current trends in bladder cancer in England and Wales. J Urol 2004; 172: 10515.
  • 4
    Colt JS, Baris D, Stewart P, Schned AR, Heaney JA, Mott LA, Silverman D, Karagas M. Occupation and bladder cancer risk in a population-based case-control study in New Hampshire. Cancer Causes Control 2004; 15: 75969.
  • 5
    Castelao JE, Yuan JM, Skipper PL, Tannenbaum SR, Gago-Dominguez M, Crowder JS, Ross RK, Yu MC. Gender-and smoking related bladder cancer risks. J Natl Cancer Inst 2001; 93: 53845.
  • 6
    Hartge P, Harvey EB, Linehan WM, Silverman DT, Sullivan JW, Hoover RN, Fraumeni JF,Jr. Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst 1990; 82: 163640.
  • 7
    Terada S, Suzuki N, Uchide K, Akasofu K, Nishida E. Effect of testosterone on the development of bladder tumors and calculi in female rats. Gynecol Obstet Invest 1992; 34: 10510.
  • 8
    Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972; 8: 58794.
  • 9
    IARC Working Group. Hormonal contraception and post menopausal hormonal therapy. IARC monographs on the evaluation of carcinogenic risks to humans, vol. 72. IARC, Lyon, 1999. 1492.
  • 10
    Miller AB, Barclay TH, Choi NM, Grace MG, Wall C, Plante M, Howe GR, Cinader B, Davis FG. A study of cancer, parity and age at first birth. J Chronic Dis 1980; 33: 595605.
  • 11
    Plesko I, Preston-Martin S, Day NE, Tzonou A, Dimitrova E, Somogyi J. Parity and cancer risk in Slovakia. Int J Cancer 1985; 36: 52933.
  • 12
    Green A, Beral V, Moser K. Mortality in women in relation to their childbearing history. BMJ 1988; 297(6645): 3915.
  • 13
    Cantor KP, Lynch CF, Johnson D. Bladder cancer, parity, and age at first birth. Cancer Causes Control 1992; 3: 5762.
  • 14
    Pelucchi C, La Vecchia C, Negri E, Dal Maso L, Franceschi S. Smoking and other risk factors for bladder cancer in women. Prev Med 2002; 35: 11420.
  • 15
    McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006; 163: 23644.
  • 16
    Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994; 5: 491500.
  • 17
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 48591.
  • 18
    Lacey JV,Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 33441.
  • 19
    Kato I, Toniolo P, Koenig KL, Kahn A, Schymura M, Zeleniuch-Jacquotte A. Comparison of active and cancer registry-based follow-up for breast cancer in a prospective cohort study. Am J Epidemiol 1999; 149: 3728.
  • 20
    Breslow NE, Day NE. Statistical methods in cancer research. In: Breslow NE, Day NE, eds. The design and analysis of cohort studies, vol. 2. Lyon: IARC Scientific Publications, 1987, 1406.
  • 21
    Preston DL, Lubin J, Pierce DA, McConney ME. EPICURE [software], release 2.0 edn. Seattle, WA: HiroSoft International, 1996.
  • 22
    McKnight B, Cook LS, Weiss NS. Logistic regression analysis for more than one characteristic of exposure. Am J Epidemiol 1999; 149: 98492.
  • 23
    La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 2001; 39: 97115.
  • 24
    Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 1996; 67: 32732.
  • 25
    Olsson H, Bladstrom A, Ingvar C. Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet Gynecol 2003; 102: 56570.
  • 26
    Schairer C, Hartge P, Hoover RN, Silverman DT. Racial differences in bladder cancer risk: a case-control study. Am J Epidemiol 1988; 128: 102737.
  • 27
    D'Avanzo B, La Vecchia C, Negri E, Decarli A, Benichou J. Attributable risks for bladder cancer in Northern Italy. Ann Epidemiol 2005; 5: 42731.
  • 28
    Mueller E, Latini J, Lux M, Stablein U, Brubaker L, Kreder K, Fitzgerald MP. Gender differences in 24-hour urinary diaries of asymptomatic North American adults. J Urol 2005; 173: 49092.
  • 29
    Andrew A, Schned AR, Heaney JA, Karagas MR. Bladder cancer risk and personal hair dye use. Int J Cancer 2004; 109: 5816.
  • 30
    Viel JF, Challier B. Bladder cancer among French farmers: does exposure to pesticides in vineyards play a part? Occup Environ Med 53: 58792.
  • 31
    Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ, Speizer FE, Willett WC. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997; 56: 3738.
  • 32
    Bean JA, Leeper JD, Wallace RB, Sherman BM, Jagger H. Variations in the reporting of menstrual histories. Am J Epidemiol 1979; 109: 1815.